InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.10
(
0.09%
)
Bitcoin
63,120.12
(
-0.06%
)
Post# of 252311
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: genisi post# 122404

Monday, 06/27/2011 9:47:59 PM

Monday, June 27, 2011 9:47:59 PM

Post# of 252311

Different approaches but all aiming Abeta: Cytos (partner with NVS) has a peptide vaccine in phase II, Transition Therapeutics (partner with Elan) with a scyllo-inositol, NeuroGenetic, EnVivo, and Satori are all in the gamma secretase modulators area and CoMentis (partner with Astellas) has a BACE inhibitor.

Thanks genisi. LGND also has royalty rights to a BACE inhibitor being developed by MRK in Phase 1 I believe.

Any of these that you view as more promising? The Phase 2 results for TTHI's ELND005 didn't exactly strike me as too promising.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up